Drug Profile
SUN 13834
Alternative Names: SUN13834Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Asubio Pharma
- Class Skin disorder therapies
- Mechanism of Action Chymase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 30 Jun 2012 Discontinued - Phase-II for Atopic dermatitis in USA (PO)
- 04 Aug 2011 Phase-II development in Atopic dermatitis is ongoing in USA
- 15 Feb 2011 SUN 13834 is available for licensing as of 15 Feb 2011. http://www.asubio.com